{
  "target": "Please tell me about Combretastatin A-1",
  "orig": "Currently, it is not yet approved for use in clinical practice.",
  "alt": "It has not yet been approved by the FDA for use in cancer treatment, but clinical trials are ongoing to evaluate its safety and efficacy.",
  "prefix": "Combretastatin A-1 is a microtubule-binding agent that has shown promising results in cancer research. It is a natural compound extracted from the bark of the African tree Combretum caffrum, and its anti-tumor activity is thought to be a result of its ability to inhibit the formation of new blood vessels (angiogenesis) in tumors. Studies have shown that Combretastatin A-1 can induce the rapid collapse of tumor blood vessels and subsequently cause tumor cell death due to a lack of oxygen and nutrients. This makes it a potential therapy for solid tumors, such as lung, breast, and colorectal cancer. Combretastatin A-1 has also been studied in combination with other chemotherapy drugs, and results have shown that it can enhance the efficacy of these drugs. However, more research is needed to fully understand the mechanisms of action of Combretastatin A-1 and its potential as a cancer therapy.",
  "triple": [
    [
      "it",
      "approved",
      "for use in clinical practice."
    ],
    "compactie",
    661
  ],
  "tag": "ok",
  "wrong": "none",
  "explanation": null
}